GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
14 nov. 2024 07h00 HE
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery...
FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression
12 nov. 2024 08h11 HE
|
Magstim EGI
FDA clears Magstim INSPIRE Transcranial Magnetic Stimulation TMS system to treat patients with Depression, OCD, Anxious Depression
Two in Five Americans Say Their Mood Worsens in Winter; 29% Say “Falling Back” Hurts Their Mental Health
30 oct. 2024 10h00 HE
|
American Psychiatric Association
Washington, D.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- As the nation “falls back” to standard time, Americans are twice as likely to say their mood declines in the winter (41%) as they are to say it...
Nexstim Receives NBS System 5 Order from European Customer
02 oct. 2024 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS...
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
03 sept. 2024 07h05 HE
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label...
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
03 sept. 2024 07h00 HE
|
GH Research PLC
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
Anxiety Disorders and Depression Treatment Global Market Report 2024-2032: Sturdy Medication Pipelines to Support Development, Economic Cost of Mental Illnesses to Drive Demand
30 août 2024 04h15 HE
|
Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Anxiety Disorders and Depression Treatment Global Market Report, Forecast by Product, Indication, Country and Company Analysis 2024-2032" report has...
Solace Psychology Announce New Anxiety and Depression Counselling Services in Melbourne
28 août 2024 09h00 HE
|
Solace Psychology
Carlton North, VIC, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Solace Psychology, regarded locally as the best psychologist melbourne, is happy to announce the launch of its anxiety and depression...
Digital Health App Data is used for Award-winning study that demonstrates correlation between temperature and depression
25 juil. 2024 09h13 HE
|
juli
Boston, July 25, 2024 (GLOBE NEWSWIRE) -- Dr. Pip Clery from University College London (UCL) has been awarded the 2024 Royal College of Psychiatrists International Congress poster prize in the...
Psychedelic Drug (Ketamine, Psilocybin) Research Report 2024: A Global $4.6 Billion Market by 2030 - Strategic Analysis, Trends, Forecasts and Competitive Analysis 2018-2023 & 2024-2030
24 juil. 2024 09h50 HE
|
Research and Markets
Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "Psychedelic Drug Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...